Avanir's AVP-825 meets in COMPASS migraine trial

Avanir Pharmaceuticals Inc. (NASDAQ:AVNR) said intranasal AVP-825 met the primary endpoint of reducing headache pain intensity vs. oral sumatriptan in the 275-patient, double-blind Phase IIIb COMPASS ...